Clearance of Leishmania donovani from the liver of BALB/c mice results in local resistance to re-infection.

K. C. Carter, A. J. Baillie, J. Alexander, T. F. Dolan

Research output: Chapter in Book/Report/Conference proceedingChapter


Relapse occurs in 5–30% of cases of visceral leishmaniasis (Chulay et al., 1983; Sanyal and Arora, 1979). This could be caused either by treatment failure, or because patients become re-infected after successful chemotherapy. As the majority of individuals who acquire Leishmania donovani infections live in endemic areas, it is highly likely that they would be exposed to the parasite again, but what effect chemotheraphy has on the immunity of the host and resistance to re-infection has received little attention. However, it is well known that many of the immunological responses depressed during active infection are increased following chemotherapy. Thus after treatment patients develop positive responses in delayed hypersensitivity skin tests (Manson-Bahr, 1959) and their lymphocytes respond to in vitro Stimulation with specific antigen (Sacks et al., 1987).
Original languageEnglish
Title of host publicationLeishmaniasis
Subtitle of host publicationthe current status and new strategies for control
Place of PublicationBoston
PublisherSpringer Science + Business Media
Number of pages7
ISBN (Print)9781461288626
Publication statusPublished - 1989

Publication series

NameNATO-ASI Series A


  • visceral leishmaniasis
  • parasite burden
  • mycobacterium bovis
  • challenge infection
  • Muramyl Dipeptide


Dive into the research topics of 'Clearance of Leishmania donovani from the liver of BALB/c mice results in local resistance to re-infection.'. Together they form a unique fingerprint.

Cite this